

## Supplementary Table 1: DOAC Concentration Ranges from Phase III trials

### Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants, *CNS Drugs*

Amichai Perlman, Rachel Goldstein, Lotan Choshen Cohen, Bruria Hirsh-Racah, David Hakimian, Ilan Matok, Yosef Kalish, Daniel E. Singer, Mordechai Muszkat

	Apixaban					Rivaroxaban				Dabigatran		
Indication	Stroke prevention in NVAf*		Treatment PE/VTE*			Stroke prevention in NVAf*		Treatment PE/VTE*	Prevention after hip surgery*	Stroke prevention in NVAf**		Treatment PE/VTE***
Dose	5 mg bid	2.5 mg bid	10 mg bid	5 mg bid	2.5 mg bid	20 mg qd	15 mg qd	20 mg qd	10 mg qd	150 mg bid	110 mg bid	150 mg bid
Peak concentration (ng/mL)	171 (91-321)	123 (69-221)	251 (111-572)	132 (59-302)	67 (30-153)	249 (184-343)	229 (178-313)	270 (189-419)	125 (91-196)	184 (74-383)	133 (52-275)	175 (117-275)
References	[1–3]	[1]	[1]	[1,2]	[1]	[2–4]	[4]	[2,4]	[4]	[5]	[5]	[2]

\* Peak concentrations are listed as median (5<sup>th</sup>-95<sup>th</sup> percentile), \*\* listed as median (10<sup>th</sup>-90<sup>th</sup> percentile), \*\*\* listed as median (25<sup>th</sup>-75<sup>th</sup> percentile)

1. European Medicines Agency. Eliquis - EPAR Product Information. [Internet]. [cited 2020 Jun 9]. Available from: [https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf)
2. Gosselin R, Adcock D, Bates S, Douxfils J, Favaloro E, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. *Thromb Haemost.* 2018;118:437–50.
3. Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. *JAMA Cardiol.* 2017;2:566.
4. Mueck W, Stampfuss J, Kubitzka D, Becka M. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. *Clin Pharmacokinet.* 2014;53:1–16.
5. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. *Journal of the American College of Cardiology.* 2014;63:321–8.